(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(-3.42%) $79.13
(-3.01%) $1.931
(1.16%) $2 329.50
(0.92%) $26.90
(1.45%) $961.95
(-0.39%) $0.933
(-0.55%) $11.04
(-0.24%) $0.798
(-0.48%) $93.00
Live Chart Being Loaded With Signals
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories...
Stats | |
---|---|
Šios dienos apimtis | 1.29M |
Vidutinė apimtis | 1.07M |
Rinkos kapitalizacija | 9.48B |
EPS | $0.550 ( 2024-04-29 ) |
Kita pelno data | ( $0.440 ) 2024-06-21 |
Last Dividend | $1.087 ( 2017-01-25 ) |
Next Dividend | $0 ( N/A ) |
P/E | 27.98 |
ATR14 | $0.0420 (0.10%) |
Tūris Koreliacija
Qiagen NV Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Qiagen NV Koreliacija - Valiuta/Žaliavos
Qiagen NV Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $1.97B |
Bruto pelnas: | $1.22B (62.23 %) |
EPS: | $1.540 |
FY | 2023 |
Pajamos: | $1.97B |
Bruto pelnas: | $1.22B (62.23 %) |
EPS: | $1.540 |
FY | 2022 |
Pajamos: | $2.14B |
Bruto pelnas: | $1.38B (64.65 %) |
EPS: | $1.920 |
FY | 2021 |
Pajamos: | $2.25B |
Bruto pelnas: | $1.45B (64.43 %) |
EPS: | $2.25 |
Financial Reports:
No articles found.
Qiagen NV Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.00208 | 2002-12-26 |
Last Dividend | $1.087 | 2017-01-25 |
Next Dividend | $0 | N/A |
Payout Date | 2017-01-31 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $1.089 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.39 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.37 | |
Div. Directional Score | 7.23 | -- |
Year | Amount | Yield |
---|---|---|
2002 | $0.00208 | 0.01% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $1.087 | 3.71% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
ZTR | Dividend King | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
ORC | Dividend Royal | 2023-11-29 | Monthly | 12 | 9.23% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
NCZ | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.79% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.174 | 1.500 | 6.53 | 9.79 | [0 - 0.5] |
returnOnAssetsTTM | 0.0558 | 1.200 | 8.14 | 9.77 | [0 - 0.3] |
returnOnEquityTTM | 0.0930 | 1.500 | -0.0782 | -0.117 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.990 | 0.800 | 5.05 | 4.04 | [1 - 3] |
quickRatioTTM | 1.458 | 0.800 | 6.13 | 4.90 | [0.8 - 2.5] |
cashRatioTTM | 0.619 | 1.500 | 7.67 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.251 | -1.500 | 5.82 | -8.74 | [0 - 0.6] |
interestCoverageTTM | 8.73 | 1.000 | 7.88 | 7.88 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.08 | 2.00 | 9.31 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.340 | 2.00 | 9.33 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.402 | -1.500 | 8.39 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.643 | 1.000 | 2.62 | 2.62 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.237 | 1.000 | 7.26 | 7.26 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.300 | 1.000 | 9.45 | 9.45 | [0.2 - 2] |
assetTurnoverTTM | 0.321 | 0.800 | -1.191 | -0.953 | [0.5 - 2] |
Total Score | 10.09 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 27.46 | 1.000 | 7.33 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0930 | 2.50 | -0.0503 | -0.117 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.340 | 2.00 | 9.55 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.12 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.08 | 2.00 | 9.31 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.488 | 1.500 | -0.0789 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.234 | 1.000 | 6.66 | 0 | [0.1 - 0.5] |
Total Score | 4.37 |
Qiagen NV
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.